Yingfeng Wei

Dr. Yingfeng Wei


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
YWYingfeng Wei
Yingfeng Wei
SGSheng Guo
Sheng Guo
JTJianhua Tang
Jianhua Tang
JWJianjun Wen
Jianjun Wen
HWHuifen Wang
Huifen Wang
QGQiuping Gu
Qiuping Gu
Background: Gastric cancer (GC) remains one of the most common digestive malignancies worldwide and ranked third causes of cancer-related death. Mounting evidence has revealed that miRNAs exert critical regulatory roles in GC development. Methods: Immunohistochemistry (IHC) and western blot assay were performed to determine the protein expression levels of neuropilin-1 (NRP1) and mRNA levels were confirmed by quantitative RT-PCR (qRT-PCR) in GC tissues. Kaplan–Meier analysis was performed to evaluate the prognostic value of NRP1 in GC. Knockdown of NRP1 was conducted to analyse its function in vitro and vivo. Luciferase reporter assay, western blot and qRT-qPCR were employed to identify the miRNAs which directly targeted NRP1. Furthermore, Bioinformatics analysis and experimental verification were used to explore the potential molecular mechanism and signalling pathway. Results: In the current study, we revealed that NRP1 was highly expressed in GC tumor tissues and was associated with poor prognosis in GC patients. NRP1 knockdown inhibited GC cell growth, migration and invasion in vitro, while suppressed GC xenograft tumor development in vivo. Bioinformatics analysis predicted that miR-19b-3p down-regulated NRP1 expression by targeting its 3′-UTR. Functional assay demonstrated that miR-19b-3p inhibited GC cell growth, migration and invasion via negatively regulating NRP1. Overexpression NRP1 partially reversed the regulatory effect of miR-19b-3p. Moreover, we showed that miR-19b-3p/NRP1 axis regulated the epithelial-to-mesenchymal transition and focal adhesion in GC, which might contribute the GC development and progression. Conclusions: Taken together, our findings suggest a regulatory network of miR-19b-3p/NRP1 in GC development. The miR-19b-3p/NRP1 axis might be further explored as a potential diagnostic and therapeutic target in GC.

29 February 2024 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
LLLi Liu
Li Liu
YWYingfeng Wei
Yingfeng Wei
NXNingSheng Xie
NingSheng Xie
HCHong Cai
Hong Cai
YLYe Lin
Ye Lin
This study aimed to elucidate the effect of mitochondria-targeted reactive oxygen species (ROS) blockor SS-31 on hepatic stellate cells (HSC) activation during liver fibrosis. TGF-β1 was employed to induce HSC activation, while MitoSOX Red was utilized to assess the presence of mitochondrial ROS. The mitochondrial membrane potential (MMP) was measured using the JC-1 probe, and the ATP level was determined using a specific kit. The proliferation of HSCs was assessed using CCK-8 and colony formation assays, whereas flow cytometry was employed to detect HSC apoptosis. Fibrotic markers (COL1A1 and α-SMA) and NLRP3 inflammasome components (NLRP3, caspase-1, and ASC) were analyzed via Western blotting. Liver fibrosis was induced in mice using CCl4, and subsequently, histopathological changes were observed through HE staining and Masson staining. In TGF-β1-activated HSCs, mitochondrial ROS expression increased, MMP and ATP content decreased, indicating mitochondrial damage. After TGF-β1 induction, HSC proliferation increased, apoptosis decreased, and COL1A1, α-SMA, and NLRP3 inflammasome protein expression increased. After SS-31 treatment, mitochondrial ROS expression decreased, MMP recovered, ATP level increased, HSC proliferation decreased, apoptosis increased, and the expressions of COL1A1, α-SMA, and NLRP3 inflammasome decreased. NLRP3 blockor MCC950 treatment blocked HSC activation. CCL4-induced liver fibrosis mice had inflammatory cell infiltration and significant collagen fiber deposition in the liver. After SS-31 treatment, liver inflammation and collagen deposition were significantly reduced. SS-31, as a mitochondria-targeted ROS blockor, can block HSC activation by regulating the NLRP3 inflammasome, thereby alleviating liver fibrosis.

3 December 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YWYingfeng Wei
Yingfeng Wei
SHShenggang Huang
Shenggang Huang
CZChunping Zhu
Chunping Zhu
JHJiaming Huang
Jiaming Huang
To assess whether Histoacryl injection with clips is superior to Histoacryl injection alone in terms of efficacy and safety. Patients with gastric varices

20 February 2026 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
XLXinlan Liu
Xinlan Liu
RCRui Cai
Rui Cai
YMYuting Meng
Yuting Meng
YXYang Xu
Yang Xu
BWBaohua Wang
Baohua Wang
HDHongyan Diao
Hongyan Diao

24 September 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
LLLi Liu
Li Liu
PYPeng Ye
Peng Ye
QGQiuping Gu
Qiuping Gu
LZLing Zeng
Ling Zeng
LLLijuan Liang
Lijuan Liang
YWYingfeng Wei
Yingfeng Wei
Objective: To examine the association between metabolic abnormalities and liver fibrosis in patients with chronic hepatitis B and develop a simple predictive index. Methods: In this retrospective cross-sectional study, 288 patients with chronic hepatitis B were evaluated. Significant fibrosis was defined as fibrosis-4 index ≥ 1.45 or liver stiffness ≥ 7.5 kPa. Variables with P < 0.10 in the univariate analysis were entered in a backward stepwise logistic regression. A fibrosis risk index was calculated from the constant term and β coefficients of significant predictors. Diagnostic performance was assessed using receiver operating characteristic curve analysis. Results: Body mass index; fasting plasma glucose, triglyceride, uric acid, and gamma-glutamyl transferase levels; and presence of fatty liver and diabetes were independent predictors of fibrosis. The fibrosis risk index showed excellent discrimination (area under the curve = 0.928, 95% confidence interval: 0.898–0.954). The optimal cutoff (0.000148) yielded 91.6% sensitivity and 76.4% specificity. Conclusion: Metabolic abnormalities are independently associated with liver fibrosis in patients with chronic hepatitis B patients. The fibrosis risk index is a simple, noninvasive tool that identifies high-risk patients for timely intervention.